Are prostate cancer drug approvals going to be affected by FDA shutdown?

The U.S. Food and Drug Administration (FDA) has clearly indicated that extension of the current “partial shutdown” of the government will, in the not too distant future, start to delay approvals of new drugs and diagnostics and new indications for currently marketed drugs. … READ MORE …

Taregted therapy and companion diagnostic: the AEZS-108 story

Here’s a clear signal that prostate cancer is entering the world of targeted therapeutics associated with specific companion diagnostics: the Canadian company Aeterna Zentaris has announced a partnership to develop a companion diagnostic to identify patients likely to respond to their targeted therapy AEZS-108. … READ MORE …

What’s in the prostate cancer news: Friday, August 15

In today’s prostate cancer news update we report on:

  • Awareness of the PSA test in men with other recognized health risks
  • A new urine test that may differentiate between prostate cancer and BPH
  • Markers for the likelihood of effectiveness of androgen deprivation from an ongoing Finnish multicenter trial … READ MORE …

New gene-based diagnostic test for prostate cancer

Health Discovery Corporation (HDC)  has announced the successful completion of a double-blind, Phase III trial of its new gene-based molecular diagnostic test for prostate cancer. … READ MORE …